Cardiovascular Reviews

Clinical Study on Self-Made Lixin Granules Combined with Natriuretic Peptide in the Treatment of Refractory Heart Failure

Yang Yu — 2023-12-28

Objective: To analyze the clinical effects of the combined application of self-made Lixin Granule and natriuretic peptide in treating refractory heart failure. Methods: From January 2022 to June 2023, 40 patients with refractory heart failure were randomly divided into groups using the envelope method. A reference group (n = 20) received conventional Western medicine treatment, while an observation group (n = 20) received self-made Lixin Granules and natriuretic peptide. Clinical efficacy, heart failure scores, traditional Chinese medicine (TCM syndrome scores, inspection indicators, and adverse reactions of the two groups were compared. Results: The effective treatment rate in the observation group was significantly higher than that in the reference group (P < 0.05). There were no significant differences in heart failure scores and traditional Chinese medicine (TCM) syndrome scores between the two groups before treatment (P > 0.05). However, both scores in the observation group were lower than those in the reference group after treatment (P < 0.05). Before treatment, there were no significant differences in the inspection indicators between the two groups (P > 0.05). After treatment, the left ventricular ejection fraction (LVEF) of the observation group was higher than that of the reference group, while the N-terminal pro b-type natriuretic peptide (NT-proBNP) level and fractional shortening (FS) of the observation group were lower than those of the reference group (P < 0.05). There were no apparent adverse reactions in either group during treatment. Conclusion: The combined application of self-made Lixin Granules and natriuretic peptide in treating refractory heart failure improved clinical efficacy, alleviation of clinical symptoms, and enhanced cardiac function. This approach is deemed safe and holds high application value.

Research Progress on Dexmedetomidine Regulating Autophagy in the Treatment of Acute Lung Injury

Guanrong Li — 2023-12-28

Dexmedetomidine, extensively utilized as an intravenous anesthetic in anesthesia, intensive care units, and other related medical departments, exhibits significant anti-inflammatory effects while inducing sedation. Numerous studies have demonstrated its capability to regulate autophagy, thereby exerting potent anti-inflammatory effects and offering therapeutic benefits in the treatment of acute lung injury. This article comprehensively reviews the mechanisms underlying autophagy, the role of dexmedetomidine in autophagy regulation, and the protective effects it conders in the context of acute lung injury. By doing so, it contributes positively to the arsenal of strategies aimed at both preventing and treating acute lung injury.

Vascular Access Blood Purification Treatments in Chronic Renal Failure: Impact on Quality of Life

Yuechun Cao — 2023-12-28

Objective: To observe the effects of blood purification treatment and assess the prognostic impact of different vascular pathways on patients with chronic renal failure (CRF). Methods: A retrospective analysis of clinical data was conducted on 68 CRF cases, categorizing them based on their choice of blood purification vascular access. Group A received an autologous arteriovenous fistula, Group B received an internal jugular vein tunneled polyester sleeve catheter, and Group C received a polytetrafluoroethylene graft vascular fistula. Clinically relevant observation indicators, complication rates, and quality of life scores among the three groups were compared. Results: No significant differences were found between the three groups regarding observed values of clinically relevant indicators and quality of life scores (P > 0.05). When comparing thromboembolism rates Group A had the highest rate, followed by Group C and Group B; for infection rate comparison, Group C had the highest rate, followed by Group B and Group A (P < 0.05). Conclusion: In comparison with the other two vascular access methods, although autologous arteriovenous fistula poses a higher risk of thromboembolism, it exhibits a lower infection rate. Therefore, it is recommended as the preferred vascular access form for blood purification in patients with CRF. If this approach is unavailable, careful consideration should be given. The use of an internal jugular vein with a tunneled polyester sleeve catheter is suggested to better ensure the effectiveness and safety of the patient’s treatment.

Evaluating the Efficacy of Interventional Approaches for Cardiac Arrhythmias in Acute Myocardial Infarction

Bin Wang — 2023-12-28

Objective: To assess the effectiveness of interventional treatments for cardiac arrhythmias in acute myocardial infarction (AMI). Methods: Eighty AMI patients admitted between August 2022 and August 2023 were selected and randomly assigned into groups using the random number table method. The control group (n = 40) received conventional thrombolytic treatment, while the observation group (n = 40) underwent percutaneous coronary intervention (PCI). Clinical effects were compared between the two groups. Results: Before treatment, there were no significant differences in heart rate indicators, cardiac function indicators, and physiological indicators between the two groups (P > 0.05). After treatment, the observation group showed significantly improved heart rate indicators, cardiac function indicators, and physiological indicators compared to the control group (P < 0.05). The adverse reaction rates in the observation group were lower than in the control group (P < 0.05). Conclusion: PCI treatment demonstrated significant improvements in heart rate, cardiac function, and physiological indicators among AMI patients, leading to a reduced incidence of adverse reactions such as arrhythmia. The overall effect is deemed significant.

Discussion on the Treatment Methods and Value of the No-Reflow Phenomenon During Percutaneous Coronary Intervention

Wenying Ma — 2023-12-28

Objective: To explore the treatment methods and value of the no-reflow phenomenon during percutaneous coronary intervention (PCI). Methods: 180 patients with acute myocardial infarction (AMI) who underwent PCI treatment at the First Hospital of Hebei Medical University from November 2020 to December 2022 were selected and divided into Group A, Group B, and Group C by random number table extraction method, each group included 60 cases. Group A received intracoronary injection of recombinant human urokinase and Group B received intracoronary injection of diltiazem. Group C adopted a targeted drug administration strategy of “front and back pinch method,” where targeted thrombolysis was performed in the target vessel before the stent was released to quickly dissolve the residual thrombus near the lesion and the small distal thrombus; recombinant human urokinase was subsequently injected in the targeted vessel. The incidence of cardiovascular events, cardiac function, and quality of life of the three groups were analyzed. Results: After the intervention, the incidence rates of angina pectoris, heart failure, and recurrent myocardial infarction in Group C were lower than those in Group B (P < 0.05); the overall incidence rate was the lowest in Group C, followed by Group A and Group B; after intervention, left ventricular end-diastolic diameter, end-systolic diameter, and ejection fraction in Groups A and C were all better than those of group B (P < 0.05), and Group C was better than Group A; after intervention, the scores of different dimensions of quality of life in Groups A and C were higher than those of Group B (P < 0.05). Conclusion: AMI patients are prone to the no-reflow phenomenon after PCI treatment. Using recombinant human urokinase to complete the “front and back pinch method” can effectively improve the no-reflow phenomenon, reduce the incidence of cardiovascular events, optimize cardiac function, and improve the patient’s quality of life and survival rate.